Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN).  The company expects to have efficacy data from this study in the second half of 2011.  The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

"2011 will be a very important year for Sangamo's ZFP Therapeutic programs," said Edward Lanphier, Sangamo's president and CEO. "In our most advanced clinical program, a disease-modifying approach for DN, we have met our goal of fully accruing our Phase 2b study by the end of 2010, thus ensuring that the data from this trial will be available in the second half of 2011.   In addition, we will present data from our Phase 1 trials of a ZFP Therapeutic approach to HIV/AIDS in the first quarter of this year.  We also recently announced significant advances in our preclinical pipeline. In December 2010, data from studies of a ZFP Therapeutic for Parkinson's disease (PD) were published^*and this drug candidate is currently being evaluated in primate models of PD. In addition, at the American Society of Hematology (ASH) meeting, we presented the first example of systemic delivery of a ZFP nuclease (ZFN) resulting in therapeutic correction of a hemophilia B in a mouse model, highlighting the broad therapeutic potential of our ZFP technology platform.  These clinical and preclinical advances continue to demonstrate the value of our ZFP Therapeutic pipeline and our commitment to address major unmet medical needs for which functioning at the DNA level is uniquely appropriate to provide a therapeutic solution for patients."

Mr. Lanphier will provide an update on the company's ZFP Therapeutic pipeline and an overview of the company's business strategy and objectives for 2011 during his presentation at the 29th Annual J.P. Morgan Healthcare Conference at 12:30 pm PT, on Thursday, January 13, 2011.  The presentation will be webcast and available at http://investor.sangamo.com/events.cfm.